You are here:

Forthcoming Submissions:

PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
cabozantinib (Cabometyx) Ipsen Ltd Full submission 6/03/2017 2/05/2017 12/06/2017
carfilzomib (Kyprolis) Amgen Ltd Full submission 3/04/2017 Q3 2017 Q3 2017
nivolumab (Opdivo) for Hodgkin lymphoma Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 3/04/2017 6/06/2017 10/07/2017
nivolumab (Opdivo) for RCC Bristol-Myers Squibb Pharmaceuticals Ltd Resubmission 6/03/2017 2/05/2017 12/06/2017
nivolumab (Opdivo) SCCHN Bristol-Myers Squibb Pharmaceuticals Ltd Full submission 5/06/2017 Q3 2017 Q3 2017
pembrolizumab (Keytruda) - 1st Line NSCLC MSD Full submission 3/04/2017 6/06/2017 10/07/2017
pertuzumab (Perjeta) Roche Resubmission 6/02/2017 2/05/2017 12/06/2017
venetoclax (Venclyxto) AbbVie Ltd Full submission 1/05/2017 Q3 2017 Q3 2017

Non-PACE medicines

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due

Medicines with advice withheld pending product availability

Name Manufacturer Submission Type Patient Group Submission Deadline SMC Meeting Date Advice Due
dinutuximab (Unituxin) United Therapeutics Full submission 31/10/2015 6/01/2016 TBC

Back